SILENCE THERAPEUTICS PLC SPON ADS EACH REP 3 ORD SHS SLN 深 沪
等待开盘 12-19 09:30:00 美东时间
6.18
-0.070
-1.12%
华盛通- 最 高6.33
- 今 开6.26
- 成交量 5.53万股
- 最 低 6.1261
- 昨 收 6.25
- 总市值 2.92亿
- 52周最高 8.08
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.97
- 委 比 -27.78%
- 总股本 4723.39万
- 历史最高 35.00
- 量 比 0.49
- 振 幅 3.26%
- 历史最低 1.97
- 每 手 1
- 风险率 1.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Silence Therapeutics President And CEO Craig Tooman Steps Down; Chairman Iain Ross Named Interim Leader
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the
12-15 21:17
Silence Therapeutics Q3 EPS $(0.15) Beats $(0.28) Estimate, Sales $159.000K Miss $4.414M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 46.43 percent. This is a 40 percent increase over losses of $(0.25) per share from
11-06 20:39
Silence Therapeutics Completes Patient Enrollment in Phase 2 Study of Divesiran
Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced it has completed patient enrollment in the SANRECO Phase 2 study of
10-23 19:34
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.
09-16 18:49
Michael Davidson Resigns from Silence Therapeutics Board
The latest announcement is out from Silence Therapeutics ( ($SLN) ). On August ...
08-14 18:57
Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $35 Price Target
Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $35 price target.
08-08 19:57
Silence Therapeutics Q2 EPS $(0.19) Beats $(0.23) Estimate, Sales $224.000K Miss $5.430M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 35.71 percent decrease over losses of $(0.14) per share
08-07 19:55
Silence Therapeutics Passes Key Resolutions at AGM
Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On June 26, 2025...
06-27 19:29
美股大行评级 | 潜在涨幅290.69%！乌龙制药获丰业银行升目标价至47美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140565699993591809.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持乌龙制药(URGN)"跑赢大市"评级，目标价从23美元升至47美元</p> <p>• Guggenheim：维持ADC Therapeutics(ADCT)"买入"评级，目标价从7美元升至10美元</p>
06-16 08:40
